Engineering therapeutic antibodies targeting G-protein-coupled receptors

Migyeong Jo, Sang Taek Jung

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

G-protein-coupled receptors (GPCRs) are one of the most attractive therapeutic target classes because of their critical roles in intracellular signaling and their clinical relevance to a variety of diseases, including cancer, infection and inflammation. However, high conformational variability, the small exposed area of extracellular epitopes and difficulty in the preparation of GPCR antigens have delayed both the isolation of therapeutic anti-GPCR antibodies as well as studies on the structure, function and biochemical mechanisms of GPCRs. To overcome the challenges in generating highly specific anti-GPCR antibodies with enhanced efficacy and safety, various forms of antigens have been successfully designed and employed for screening with newly emerged systems based on laboratory animal immunization and high-throughput-directed evolution.

Original languageEnglish
Pages (from-to)e207
JournalExperimental & molecular medicine
Volume48
DOIs
Publication statusPublished - 2016 Feb 5
Externally publishedYes

Fingerprint

G-Protein-Coupled Receptors
Antibodies
Immunization
Therapeutics
Antigens
Laboratory Animals
Epitopes
Screening
Animals
Throughput
Inflammation
Safety
Infection
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Engineering therapeutic antibodies targeting G-protein-coupled receptors. / Jo, Migyeong; Jung, Sang Taek.

In: Experimental & molecular medicine, Vol. 48, 05.02.2016, p. e207.

Research output: Contribution to journalReview article

@article{6a571efc3cca4df39bb192de9077b75f,
title = "Engineering therapeutic antibodies targeting G-protein-coupled receptors",
abstract = "G-protein-coupled receptors (GPCRs) are one of the most attractive therapeutic target classes because of their critical roles in intracellular signaling and their clinical relevance to a variety of diseases, including cancer, infection and inflammation. However, high conformational variability, the small exposed area of extracellular epitopes and difficulty in the preparation of GPCR antigens have delayed both the isolation of therapeutic anti-GPCR antibodies as well as studies on the structure, function and biochemical mechanisms of GPCRs. To overcome the challenges in generating highly specific anti-GPCR antibodies with enhanced efficacy and safety, various forms of antigens have been successfully designed and employed for screening with newly emerged systems based on laboratory animal immunization and high-throughput-directed evolution.",
author = "Migyeong Jo and Jung, {Sang Taek}",
year = "2016",
month = "2",
day = "5",
doi = "10.1038/emm.2015.105",
language = "English",
volume = "48",
pages = "e207",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",

}

TY - JOUR

T1 - Engineering therapeutic antibodies targeting G-protein-coupled receptors

AU - Jo, Migyeong

AU - Jung, Sang Taek

PY - 2016/2/5

Y1 - 2016/2/5

N2 - G-protein-coupled receptors (GPCRs) are one of the most attractive therapeutic target classes because of their critical roles in intracellular signaling and their clinical relevance to a variety of diseases, including cancer, infection and inflammation. However, high conformational variability, the small exposed area of extracellular epitopes and difficulty in the preparation of GPCR antigens have delayed both the isolation of therapeutic anti-GPCR antibodies as well as studies on the structure, function and biochemical mechanisms of GPCRs. To overcome the challenges in generating highly specific anti-GPCR antibodies with enhanced efficacy and safety, various forms of antigens have been successfully designed and employed for screening with newly emerged systems based on laboratory animal immunization and high-throughput-directed evolution.

AB - G-protein-coupled receptors (GPCRs) are one of the most attractive therapeutic target classes because of their critical roles in intracellular signaling and their clinical relevance to a variety of diseases, including cancer, infection and inflammation. However, high conformational variability, the small exposed area of extracellular epitopes and difficulty in the preparation of GPCR antigens have delayed both the isolation of therapeutic anti-GPCR antibodies as well as studies on the structure, function and biochemical mechanisms of GPCRs. To overcome the challenges in generating highly specific anti-GPCR antibodies with enhanced efficacy and safety, various forms of antigens have been successfully designed and employed for screening with newly emerged systems based on laboratory animal immunization and high-throughput-directed evolution.

UR - http://www.scopus.com/inward/record.url?scp=84962832391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962832391&partnerID=8YFLogxK

U2 - 10.1038/emm.2015.105

DO - 10.1038/emm.2015.105

M3 - Review article

C2 - 26846450

AN - SCOPUS:84962832391

VL - 48

SP - e207

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

ER -